Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Performance evaluation of the Simtomax® CoronaCheck rapid diagnostic test

P.J. Ducrest a, **, A. Freymond b, J.-M. Segura b, *

a GaDia SA, Route de l’ile au bois 1A, 1870 Monthey, Switzerland
b Institute of Life Technologies - School of Engineering, HES-SO // University of Applied Sciences Western Switzerland, Sion, Switzerland

** Corresponding author.

A R T I C L E   I N F O

Keywords:
SARS-CoV-2
COVID-19
Serology
Rapid test
Lateral flow immunoassay

A B S T R A C T

The aim of this study was to evaluate the diagnostic performance of Simtomax® CoronaCheck, a serology rapid diagnostic test (RDT) for the detection of IgG and IgM against SARS-CoV-2. 48 plasma samples positive for SARS-CoV-2 based on RT-PCR and 98 negative control samples were studied. Diagnostic performance of the IgG/IgM RDT was assessed against RT-PCR and the electro-chemiluminescence immunoassay (ECLI) Elecsys® Anti-SARS-CoV-2 total Ig. Overall, the RDT sensitivity was 92 % (95 % confidence interval [95 %CI]: 79 –97), specificity 97 % (95 % CI: 91 –99 %), PPV 94 % (95 % CI: 81 –96) and the NPV 96 % (95 % CI: 89 –99). When considering only samples collected > 15 days post-symptoms (DPS), the sensitivity increased to 98 % (95 %CI: 86-100) and the specificity was 97 % (95 % CI: 91 –99 %). Two samples with 180 DPS were still positive for IgG. Globally, this IgG/IgM RDT displayed a high diagnostic accuracy for SARS-CoV-2 IgG/IgM detection in plasma samples in high COVID-19 prevalence settings. It could be effectively used, in absence of facilities for routine diagnostic serology, for samples with a DPS between 15 and 180 days.

1. Introduction

SARS-CoV-2 is the etiological agent of a severe pneumonia first reported in Wuhan (Hubei, China), called 2019 Coronavirus Disease (COVID-19). Protein sequence analysis of seven proteins showed that the virus is related to the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) with similar epidemiology (Kannan et al., 2020; Zhou et al., 2020). Currently, the detection method for SARS-CoV-2 is based on viral RNA detection using Reverse-Transcription PCR (RT-PCR) but other tests such as chest computed tomography (CT) imaging or antigen/antibody testing can also be used (Li et al., 2020a,b). Serological analysis may be applied to detect past exposure to the virus and possibly if a patient has developed immunity against the virus. It is widely accepted that IgM provides the first line of defense during acute viral infections, prior to the generation of adaptive, high affinity IgG responses that are important for long term immunity and immunological memory (Li et al., 2020b). Several authors analyzed the antibody kinetics in COVID-19 patients. Zhao et al. (2020) showed that among 173 patients, the seroconversion sequentially appeared for total antibody, IgM and then IgG, with a median time of 11, 12 and 14 days after symptom onset. The majority of antibodies are produced against the most abundant protein of the virus, which is the nucleocapsid protein (NP). Therefore, serological tests that detect antibodies to NP should be the most sensitive. In addition, because the receptor-binding domain of the Spike protein (RBD-S) is the host attachment protein, antibodies against RBD-S should be very specific. Therefore, according to some authors, using one or both antigens should result in high sensitivity and specificity (Sethuraman et al., 2020). The rapid diagnostic test (RDT) Simtomax® CoronaCheck developed by Augurix SA (Switzerland) uses both antigens as described in To et al. (2020). The gold nanoparticles used for detection are conjugated with SARS-CoV-2 Receptor Binding Domain and Nucleocapsid protein with the aim to specifically bind IgM and/or IgG in COVID-19 positive samples. A recent clinical evaluation of Augurix RDT at the University Hospitals of Geneva and Lausanne (Switzerland) demonstrated high diagnostic accuracy for IgG in whole-blood, plasma and sera samples (Andrey et al., 2020; Coste et al., 2021).

The aim of this study was to evaluate the performance of this RDT with plasma samples in a high COVID-19 prevalence setting using as...
reference methods RT-PCR and an Electro-chemiluminescence immunoassay (ECLIA) Elecsys® Anti-SARS-CoV-2 total Ig (Roche, Switzerland).

2. Materials & methods

2.1. Study population and blood sample collection

Forty-eight anonymized remaining patients’ plasma-EDTA specimens, supplied by INO Specimens BioBank, ISB (Clermont-Ferrand, France), were used for this method evaluation (Fig. 1). Only laboratory-based information was used in this study. All 48 samples were from patients positive for SARS-CoV-2 based on RT-PCR measurements on nasopharyngeal swab samples using the BD SARS-CoV-2 reagent kit for the BD Max system (Becton Dickinson and Co, US). The RT-PCR analysis were performed by INO Specimens. The median CT value was 25.6 (IQR = 23.05–29.15). The plasma-EDTA specimens (n = 48) were all collected at days post symptom (DPS) of at least 10 days. A proportion of 48 % (23/48) of the plasma-EDTA specimens were additionally tested for total immunoglobulin against COVID-19 with an electro-chemiluminescence immunoassay (ECLIA) at INO Specimens BioBank (Fig. 1). As negative controls, anonymized unmatched control plasma samples (n = 98), supplied by AbBalts (Kent, UK) with a collection date before 2018, were used (Fig. 1).

2.2. Augurix IgM/IgG immunochromatographic rapid test

Commercial CE-labeled SARS-CoV-2 IgM/IgG RDT were from Augurix (Switzerland). This test detects IgG and IgM against NP and RBD-S antigens and can be used either with capillary blood, whole blood, plasma or serum. One IgM/IgG rapid test per sample was used. Following manufacturers’ instructions, 10 μL of plasma were applied for each sample. IgG and IgM responses were read after 15 min following manufacturer’s instructions, blinded to the reference method results. The tests were considered COVID-19 positive if either the IgM line or the IgG line or both lines were positive.

2.3. Electro-chemiluminescence immunoassay Elecsys® Anti-SARS-CoV-2 total Ig

ECLIA experiments were performed at INO Specimens Biobank. Elecsys® Anti-SARS-CoV-2 total Ig (Roche, Switzerland) makes use of the nucleocapsid protein of SARS-CoV-2 as antigen. This test detects the total Ig against NP antigen. Total Ig was analyzed according to manufacturer’s instructions. The assays were run on a Cobas e 601 (Roche, Switzerland) according to manufacturer’s protocol. Positivity was defined by the manufacturer as a cut-off index (COI) ≥ 1.0.

2.4. Study end points

The primary end point was to assess the accuracy of IgG/IgM detection in plasma using Augurix IgM/IgG RDT against the RT-PCR reference method, within a cohort of 48 RT-PCR confirmed COVID-19, with day post-symptoms (DPS) of ≥ 10 days, and 98 control plasma samples. The secondary end point was to assess Augurix IgG/IgM RDT performance against Electro-chemiluminescence immunoassay (ECLIA), Elecsys® Anti-SARS-CoV-2 total Ig (Roche, Switzerland).

2.5. Statistics

Vassarstats on-line tool (www.vassarstats.net) was used to calculate sensitivity (SE), specificity (SP), positive and negative predictive values (PPV, NPV), 95 % confidence intervals, median, Interquartile range (IQR) and Cohen’s kappa values. Significance (p-values) were calculated using a Mann-Whitney U test. Statistical significance was defined as p < 0.05.

3. Results

3.1. Baseline characteristics

The demographic characteristics of patients’ samples were as follows: the 48 COVID-19-positive samples were from patients older (median = 49 years old, IQR 33–58.75) compared to the healthy patients (median = 34.5 years old, IQR 18–44.75; p = 0.05). The proportion of females was 56 % (n = 20) and 51 % (n = 50) in the COVID-19 positive and in the healthy control group, respectively.

Among the COVID-19 samples, the median delay between symptom onset and sampling was 21 days (IQR 16–32 days), but not less than 10 days. The longest DPS (one single sample) was 180 days.

A detailed description of all the available information on the samples and the results of the various tests is provided in the supplementary information.

3.2. Specificity of IgG/IgM RDT on the negative control group

The diagnostic specificity of the IgG/IgM RDT was assessed on the COVID-19 negative control group with a sampling date before 2018 (n = 98). The results are shown in Tables 1 and 2. IgG/IgM RDT results were negative in 96.9 % (95/98) of the cases (95 %CI: 91–100 %). Three discordant results showed a positive IgM line while negative with RT-PCR (false positives compared to RT-PCR results). The specificity (SP) of the IgG/IgM RDT was therefore 97 % (95 % CI: 91–99 %).

Table 1

| Sample Group                      | SE % (95 % CI) | SP % (95 % CI) | PPV % (95 % CI) | NPV % (95 % CI) |
|-----------------------------------|---------------|---------------|----------------|----------------|
| All samples (n = 146); Prevalence  | 92 (79–97)    | 97 (91–99)    | 94 (81–98)     | 96 (89–99)     |
| IgG/IgM RDT vs RT-PCR             |               |               |                |                |
| Samples with DPS < 15 and negative | 57 (20–88)    | 97 (91–99)    | 57 (20–88)     | 97 (91–99)     |
| controls (n = 105); Prevalence 7/105 |               |               |                |                |
| IgG/IgM RDT vs RT-PCR             |               |               |                |                |
| Samples with DPS ≥ 15 and negative| 98 (86–100)   | 97 (91–99)    | 93 (80–98)     | 99 (94–100)    |
| controls (n = 139); Prevalence 41/139 |               |               |                |                |

RDT: Simtomax CoronaCheck rapid diagnostic test; SE: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value; ECLIA: Electro-chemiluminescence immunoassay.
The main finding of this evaluation study, using an unmatched case-control design including 67.1% (98/146) of negative control samples, is that the diagnostic accuracy of IgG/IgM Augurix RDT on plasma samples when compared to RT-PCR confirmed cases displayed a SE of 92%, a SP of 97%, a PPV of 94% and a NPV of 96%. When compared to ECLIA positive samples, the diagnostic accuracy of IgG/IgM Augurix RDT displayed a SE of 91%, a SP of 97%, a PPV of 88% and a NPV of 98%. The sensitivity (SE) of IgG/IgM Augurix RDT was not significantly different for both reference methods (p = 0.756) with strong Cohen’s kappa correlations of 89% for RDT vs RT-PCR and 87% for RDT vs ECLIA. The diagnostic accuracy of the RDT further increased when analyses were performed exclusively on samples collected after 15 DPS and exhibited excellent sensitivity (98%) and NPV (99%). For samples collected within a DPS < 15 days, the diagnostic performance was clearly poorer with 57%, 97%, 57% and 97% for SE, SP, PPV and NPV, respectively.

It is interesting to notice that the two false-negative results obtained with Augurix RDT corresponded to borderline samples in ECLIA (Cut-off index of 1.43 and 1.19) with a DPS between 10 and 15 days. The ECLIA manufacturer defines positive samples when the cut-off index (COI) value is > 1.0. This finding indicates that the analytical sensitivity of Augurix RDT is lower than the ECLIA Elecsys® Anti-SARS-CoV-2 total Ig (Roche, Switzerland) and that insufficient analytical sensitivity might at least partly explain the poor performance of the RDT test at DPS < 15 days.

For samples with DPS > 15, there is a perfect agreement between ECLIA and Augurix RDT, which can be explained by the fact that both assays target the immune response against the full-length N protein of SARS-CoV-2. The overall good specificity of the Augurix RDT might be offered by the fact that it also targets the immune response against the Receptor binding domain (RBD) of S protein.

The overall performance, in particular for DPS > 15, indicates that Augurix RDT could be fit for purpose in clinical settings where a high prevalence of COVID-19 prevails, especially in situations where ECLIA is not available. Diagnostic performance in low prevalence populations still needs to be experimentally determined and it would be interesting to validate the results on larger populations. The results of our study on plasma samples are similar with those recently published on whole blood and plasma samples, which indicated a sensitivity of Augurix RDT between 93% and 100% for samples with a DPS of > 15 days (Andreychi et al., 2020; Coste et al., 2021), but differ from prior studies using Augurix and other RDTs that observed a lower sensitivity of 56.4% for a DPS of > 21 days (Rudolf et al., 2020). However, differences in methodology and sample size between the two studies make a comparison difficult. Concerning the specificity of the test, the excellent performance observed in this study is in line with the results of preceding publications (Andreychi et al., 2020; Coste et al., 2021). Three control blood samples turned out to be IgM positive by RDT although they were collected before 2018. Non-specific binding of undefined IgM antibodies in the samples with the antigens present on the IgM line might possibly explain this finding. But overall, Augurix RDT might be a suitable choice in situations where a high PPV is instrumental.

The second notable finding of this study lies in the fact that IgG seropositivity is still present 180 days after symptom onset in spite of normal antibody decline (Long et al., 2020; Seow et al., 2020). To our knowledge, it is the first time that SARS-CoV-2 IgG seropositivity is demonstrated with RDT 180 DPS. The present study indicates also that a certain level of SARS-CoV-2 IgG is present constantly with a concentration sufficient to be detectable with RDT, from 15 days to at least 180 days post symptoms. This finding applies to the Augurix RDT and cannot be generalized to other RDTs for SARS-CoV-2 specific antibodies currently available. It would be interesting to quantitatively determine the level of IgG/IgM 180 days post symptoms onset to confirm this finding obtained with a qualitative assay.

In addition, the test provided clear results without indeterminate or
invalid measurements. There are however several limitations to this study. First, we present here the results of a method evaluation study and not a seroprevalence study. Therefore, the PPV obtained here (based on a 32.9 % proportion of cases defined as laboratory confirmed SARS-CoV-2 by RT-PCR) will be lower in a low prevalence setting, e.g. when testing the asymptomatic population. Another limitation of this validation study lies in the limited sample size leading to broad 95 % confidence intervals, requiring confirmation of these data at a larger scale. Also, here we used plasma and the test was performed in a laboratory environment; we may expect different results in real-life at patients’ bed and using capillary blood. Finally, our present conclusions only apply to the Augurix RDT, and must not be generalized to other currently available RDTs for SARS-CoV-2 specific antibodies.

In conclusion, Augurix RDT is not meant to replace a SARS-CoV-2 RT-PCR diagnostic test in the first week of the disease, but could be a reliable option for assessing the SARS-CoV-2 serology in moderate to high COVID-19 prevalence settings, i.e. when testing the sub-population of individuals having presented COVID-19 symptoms, especially in situations where automated ECLIA or ELISA are not available, with samples collected between at least 15 days and up to 180 days after the onset of symptoms.

Contributions

Percevent J Ducrest: Conceptualization, Methodology, Investigation, Formal analysis, Writing - Original Draft preparation. Antoine Freymond: Investigation, Formal analysis, Writing - Original Draft preparation. Jean-Manuel Segura: Writing - Original Draft preparation, Writing - Review & Editing preparation, Visualization

Ethical consideration

This study was evaluated by the Ethics Committee of Canton de Vaud, Lausanne, Switzerland (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign residual samples.

All necessary patient/participant consent has been obtained by the supplier of residual samples and the appropriate institutional forms have been archived.

Funding

This research was financially supported by the HES-SO Valais-Wallis.

Declaration of Competing Interest

Percevent J Ducrest has a R&D mandate with Augurix SA, the manufacturer of the RDT used in this study. Augurix SA had no role in the study design, the realization nor in result interpretation. The other authors have no conflict of interest to disclose.

Acknowledgments

We thank Augurix SA (Monthey, Switzerland) for providing SimtoCoronaCheck RDTs free-of-charge.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jviromet.2021.114178.

References

Andrey, D.O., Cohen, P., Meyer, B., et al., 2020. Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. Eur. J. Clin. Invest. 50, e13357 https://doi.org/10.1111/euci.13557.
Coste, A.T., Jaton, K., Papadimitriou-Oliveris, M., Greub, G., Crozatto, A., 2020. Comparison of SARS-CoV-2 serological tests with different antigen targets. J. Clinical. Virol. 134, 104690 https://doi.org/10.1016/j.jcv.2020.104690.
Kannan, S., Shaik Syed Ali, P., Sheerza, A., Hemalatha, K., 2020. COVID-19 (Novel Coronavirus 2019) – recent trends. Eur. Rev. Med. Pharmacol. Sci. 24, 2006–2011. https://doi.org/10.26355/eurrev_202002_20378.
Li, C., Zhao, C., Bao, J., Tang, B., Wang, Y., Gu, B., 2020a. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). Chin. Clin. Acta 510, 35–46. https://doi.org/10.1016/j.jcca.2020.06.045.
Li, Z., Yi, Y., Luo, X., et al., 2020b. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J. Med. Virol. 92, 1518–1524. https://doi.org/10.1002/jmv.25727.
Long, Q., Liu, B., Deng, H., et al., 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848. https://doi.org/10.1038/s41591-020-0897-1.
Rudolf, F., Kaltenbach, H.M., Linnik, J., Ruf, M.T., Niederhauser, C., Nickel, B., Gygax, D.,ovic, M., 2020. Clinical characterization of eleven lateral flow assays for detection of COVID-19 antibodies in a population. medRxiv. https://doi.org/10.1101/2020.08.18.201777204. 2020.08.18.201777204.
Seow, J., Graham, C., Merrick, B., et al., 2020. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Nat. Microbiol. 5, 1598–1607. https://doi.org/10.1038/s41564-020-00813-8.
Sethuraman, N., Jeremiah, S.S., Ryo, A., 2020. Interpreting diagnostic tests for SARS-CoV-2: an observational cohort study. Lancet. Infect. Dis. 20, 565–574. https://doi.org/10.1016/S1473-3099(20)30196-1.
Zhao, J., Yuan, Q., Wang, X., Liu, W., et al., 2020. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease. Clin. Infect. Dis. 344 https://doi.org/10.1093/cid/ciaa.344 ciaa.
Zhao, J., Yuan, Q., Wang, X., et al., 2020. Pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–272. https://doi.org/10.1038/s41586-020-2012-7.